The important role of CNS facilitation and inhibition for chronic pain

International Journal of Clinical Rheumatology

Volumn 8, Issue 6, 2013, Pages 639-646

  Staud, Roland ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

chronic pain; facilitation; inhibition

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; CLONIDINE; DULOXETINE; GABAPENTIN; NARCOTIC ANALGESIC AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PREGABALIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN;

ALLODYNIA; ANTINOCICEPTION; CHRONIC PAIN; FACILITATION; HUMAN; HYPERALGESIA; MEDULLA OBLONGATA; NERVE CELL INHIBITION; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; NORADRENERGIC SYSTEM; PAIN THRESHOLD; PERIAQUEDUCTAL GRAY MATTER; PERIPHERAL NERVE INJURY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; ROSTROVENTROMEDIAL MEDULLA; SEROTONINERGIC SYSTEM; SPINAL CORD DORSAL HORN; TEMPORAL SUMMATION;

EID: 84896998141     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.13.57     Document Type: Review

References (105)

1. Ebbinghaus M, Uhlig B, Richter F et al. The role of interleukin-1beta in arthritic pain: main involvement in thermal, but not mechanical, hyperalgesia in rat antigen-induced arthritis. Arthritis Rheum. 64, 3897-3907 (2012).
2. Richter F, Natura G, Ebbinghaus M et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 64, 4125-4134 (2012).
3. Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J. Neurosci. 26, 246-255 (2006).
4. Fehrenbacher JC, Burkey TH, Nicol GD, Vasko MR. Tumor necrosis factor alpha and interleukin-1beta stimulate the expression of cyclooxygenase II but do not alter prostaglandin E2 receptor mRNA levels in cultured dorsal root ganglia cells. Pain 113, 113-122 (2005).
5. von Banchet GS, Kiehl M, Schaible HG. Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat. J. Neurochem. 94, 238-248 (2005).
6. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1 beta, interleukin-6, and tumor necrosis factor-beta in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 28, 5189-5194 (2008).
7. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90, 1-6 (2001).
8. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 24, 450-455 (2001).
9. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain 9, 463-484 (2005).
10. Treede RD, Kenshalo DR, Gracely RH, Jones AK. The cortical representation of pain. Pain 79, 105-111 (1999).
11. Kenshalo DR Jr, Isensee O. Responses of primate SI cortical neurons to noxious stimuli. J. Neurophysiol. 50, 1479-1496 (1983).
12. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain 118, 279-306 (1995).
13. Tracey I. Nociceptive processing in the human brain. Curr. Opin. Neurobiol. 15, 478-487 (2005).
14. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 152(3 Suppl.), S49-S64 (2011).
15. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. N. Engl. J. Med. 368, 1388-1397 (2013).
16. Bingel U, Herken W, Teutsch S, May A. Habituation to painful stimulation involves the antinociceptive system - a 1-year follow-up of 10 participants. Pain 140, 393-394 (2008).
17. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain 10, 895-926 (2009).
18. Luscher C, Nicoll RA, Malenka RC, Muller D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat. Neurosci. 3, 545-550 (2000).
19. Mendell LM. Modifiability of spinal synapses. Physiol. Rev. 64, 260-324 (1984).
20. Sherrington CS. The Integrative Action of the Nervous System. Yale University Press, New Haven, CT, USA (1906).
21. Reynolds DV. Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science 164, 444-445 (1969).
22. Young RF, Brechner T. Electrical stimulation of the brain for relief of intractable pain due to cancer. Cancer 57, 1266-1272 (1986).
23. Mayer DJ. Analgesia produced by electrical stimulation of the brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 557-564 (1984).
24. Tracey I, Ploghaus A, Gati JS et al. Imaging attentional modulation of pain in the periaqueductal gray in humans. J. Neurosci. 22, 2748-2752 (2002).
25. Tracey I, Dunckley P. Importance of anti-and pro-nociceptive mechanisms in human disease. Gut 53, 1553-1555 (2004).
26. Fields HL, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Textbook of Pain (4th Edition). Wall PD, Melzack R (Eds). Churchill Livingstone, Edinburgh, Scotland, UK, 309-329 (1999).
27. Lei J, You HJ. Endogenous descending facilitation and inhibition differ in control of formalin intramuscularly induced persistent muscle nociception. Exp. Neurol. 248, 100-111 (2013).
28. Nir RR, Yarnitsky D, Honigman L, Granot M. Cognitive manipulation targeted at decreasing the conditioning pain perception reduces the efficacy of conditioned pain modulation. Pain 153, 170-176 (2012).
29. Lautenbacher S, Prager M, Rollman GB. Pain additivity, diffuse noxious inhibitory controls, and attention: a functional measurement analysis. Somatosens. Mot. Res. 24, 189-201 (2007).
30. Defrin R, Tsedek I, Lugasi I, Moriles I, Urca G. The interactions between spatial summation and DNIC: effect of the distance between two painful stimuli and attentional factors on pain perception. Pain 151, 489-495 (2010).
31. Fields HL, Basbaum AI, Clanton CH, Anderson SD. Nucleus raphe magnus inhibition of spinal cord dorsal horn neurons. Brain Res. 126, 441-453 (1977).
32. Fields HL, Basbaum AI. Brainstem control of spinal pain-transmission neurons. Annu. Rev. Physiol. 40, 217-248 (1978).
33. Behbehani MM, Fields HL. Evidence that an excitatory connection between the periaqueductal gray and nucleus raphe magnus mediates stimulation produced analgesia. Brain Res. 170, 85-93 (1979).
34. Gebhart GF, Sandkuhler J, Thalhammer JG, Zimmermann M. Inhibition of spinal nociceptive information by stimulation in midbrain of the cat is blocked by lidocaine microinjected in nucleus raphe magnus and medullary reticular formation. J. Neurophysiol. 50, 1446-1459 (1983).
35. Fields HL. Is there a facilitating component to central pain modulation? APS J. 1, 139-141 (1992).
36. Fields HL, Bry J, Hentall I, Zorman G. The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. J. Neurosci. 3, 2545-2552 (1983).
37. Fields HL, Heinricher MM. Anatomy and physiology of a nociceptive modulatory system. Philos. Trans. R. Soc. Lond. B Biol. Sci. 308, 361-374 (1985).
38. Ellrich J, Ulucan C, Schnell C. Are 'neutral cells' in the rostral ventro-medial medulla subtypes of on- and off-cells? Neurosci. Res. 38, 419-423 (2000).
39. Schnell C, Ulucan C, Ellrich J. Atypical on-, off- and neutral cells in the rostral ventromedial medulla oblongata in rat. Exp. Brain Res. 145, 64-75 (2002).
40. Barbaro NM, Heinricher MM, Fields HL. Putative pain modulating neurons in the rostral ventral medulla: reflex-related activity predicts effects of morphine. Brain Res. 366, 203-210 (1986).
41. Heinricher MM, Barbaro NM, Fields HL. Putative nociceptive modulating neurons in the rostral ventromedial medulla of the rat: firing of on- and off-cells is related to nociceptive responsiveness. Somatosens. Mot. Res. 6, 427-439 (1989).
42. Kim DH, Fields HL, Barbaro NM. Morphine analgesia and acute physical dependence: rapid onset of two opposing, dose-related processes. Brain Res. 516, 37-40 (1990).
43. Bederson JB, Fields HL, Barbaro NM. Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens. Mot. Res. 7, 185-203 (1990).
44. Jensen TS, Yaksh TL. Comparison of the antinociceptive effect of morphine and glutamate at coincidental sites in the periaqueductal gray and medial medulla in rats. Brain Res. 476, 1-9 (1989).
45. Heinricher MM, Morgan MM, Fields HL. Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience 48, 533-543 (1992).
46. Benedetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog. Neurobiol. 52, 109-125 (1997).
47. Eippert F, Bingel U, Schoell ED et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63, 533-543 (2009).
48. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 295, 1737-1740 (2002).
49. Zubieta JK, Bueller JA, Jackson LR et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J. Neurosci. 25, 7754-7762 (2005).
50. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J. Clin. Invest. 120, 3779-3787 (2010).
51. Oliveras JL, Hosobuchi Y, Guilbaud G, Besson JM. Analgesic electrical stimulation of the feline nucleus raphe magnus: development of tolerance and its reversal by 5-HTP. Brain Res. 146, 404-409 (1978).
52. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res. 236, 329-337 (1982).
53. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr. Neuropharmacol. 7, 331-336 (2009).
54. Cui M, Feng Y, McAdoo DJ, Willis WD. Periaqueductal gray stimulation-induced inhibition of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, serotonin, and amino acids. J. Pharmacol. Exp. Ther. 289, 868-876 (1999).
55. Yaksh TL, Wilson PR. Spinal serotonin terminal system mediates antinociception. J. Pharmacol. Exp. Ther. 208, 446-453 (1979).
56. Jensen TS, Yaksh TL. Spinal monoamine and opiate systems partly mediate the antinociceptive effects produced by glutamate at brainstem sites. Brain Res. 321, 287-297 (1984).
57. Dogrul A, Ossipov MH, Porreca F. Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res. 1280, 52-59 (2009).
58. Mason P. Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. Annu. Rev. Neurosci. 24, 737-777 (2001).
59. Wei F, Dubner R, Zou S et al. Molecular depletion of descending serotonin unmasks its novel facilitatory role in the development of persistent pain. J. Neurosci. 30, 8624-8636 (2010).
60. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol. Sci. 25, 613-617 (2004).
61. Aimone LD, Jones SL, Gebhart GF. Stimulation-produced descending inhibition from the periaqueductal gray and nucleus raphe magnus in the rat: mediation by spinal monoamines but not opioids. Pain 31, 123-136 (1987).
62. Hammond DL, Tyce GM, Yaksh TL. Efflux of 5-hydroxytryptamine and noradrenaline into spinal cord superfusates during stimulation of the rat medulla. J. Physiol. 359, 151-162 (1985).
63. Yeomans DC, Proudfit HK. Projections of substance P-immunoreactive neurons located in the ventromedial medulla to the A7 noradrenergic nucleus of the rat demonstrated using retrograde tracing combined with immunocytochemistry. Brain Res. 532, 329-332 (1990).
64. Fields HL, Heinricher MM. Central nervous system mechanisms of pain modulation. In: Wall and Melzack's Textbook of Pain. McMahon SB, Koltzenburg M, Tracey I, Turk DC (Eds). Elsevier Saunders, Burlington, MA, USA, 129-142 (2013).
65. Pertovaara A. Noradrenergic pain modulation. Prog. Neurobiol. 80, 53-83 (2006).
66. Morgan MM, Fields HL. Pronounced changes in the activity of nociceptive modulatory neurons in the rostral ventromedial medulla in response to prolonged thermal noxious stimuli. J. Neurophysiol. 72, 1161-1170 (1994).
67. Kuner R. Central mechanisms of pathological pain. Nat. Med. 16, 1258-1266 (2010).
68. Pertovaara A, Wei H, Hamalainen MM. Lidocaine in the rostroventromedial medulla and the periaqueductal gray attenuates allodynia in neuropathic rats. Neurosci. Lett. 218, 127-130 (1996).
69. Burgess SE, Gardell LR, Ossipov MH et al. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J. Neurosci. 22, 5129-5136 (2002).
70. Zhang W, Gardell S, Zhang D et al. Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain 132, 778-787 (2009).
71. Herrero JF, Laird JMA, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog. Neurobiol. 61, 169-203 (2000).
72. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91, 165-175 (2001).
73. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon RL, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99, 49-59 (2002).
74. Yarnitsky D, Arendt-Nielsen L, Bouhassira D et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur. J. Pain 14, 339 (2010).
75. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 6, 283-304 (1979).
76. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain 6, 305-327 (1979).
77. Le Bars D, Chitour D, Kraus E, Dickenson AH, Besson JM. Effect of naloxone upon diffuse noxious inhibitory controls (DNIC) in the rat. Brain Res. 204, 387-402 (1981).
78. King CD, Goodin B, Kindler LL et al. Reduction of conditioned pain modulation in humans by naltrexone: an exploratory study of the effects of pain catastrophizing. J. Behav. Med. 36, 315-327 (2013).
79. Morton CR, Maisch B, Zimmermann M. Diffuse noxious inhibitory controls of lumbar spinal neurons involve a supraspinal loop in the cat. Brain Res. 410, 347-352 (1987).
80. Villanueva L, Le Bars D. The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Biol. Res. 28, 113-125 (1995).
81. Leite-Almeida H, Valle-Fernandes A, Almeida A. Brain projections from the medullary dorsal reticular nucleus: an anterograde and retrograde tracing study in the rat. Neuroscience 140, 577-595 (2006).
82. Monconduit L, Desbois C, Villanueva L. The integrative role of the rat medullary subnucleus reticularis dorsalis in nociception. Eur. J. Neurosci. 16, 937-944 (2002).
83. Le Bars D. The whole body receptive field of dorsal horn multireceptive neurones. Brain Res. Rev. 40, 29-44 (2002).
84. Sprenger C, Bingel U, Buchel C. Treating pain with pain: supraspinal mechanisms of endogenous analgesia elicited by heterotopic noxious conditioning stimulation. Pain 152, 428-439 (2011).
85. Villanueva L. Diffuse noxious inhibitory control (DNIC) as a tool for exploring dysfunction of endogenous pain modulatory systems. Pain 143, 161-162 (2009).
86. Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. J. Pain 13, 936-944 (2012).
87. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 88, 69-78 (2000).
88. Arendt-Nielsen L, Nie HL, Laursen MB et al. Sensitization in patients with painful knee osteoarthritis. Pain 149, 573-581 (2010).
89. Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache. Pain 118, 215-223 (2005).
90. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky D. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain 104, 693-700 (2003).
91. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114, 295-302 (2005).
92. Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared with normal controls. Pain 110, 689-696 (2004).
93. Olesen SS, Brock C, Krarup AL et al. Descending inhibitory pain modulation is impaired in patients with chronic pancreatitis. Clin. Gastroenterol. Hepatol. 8, 724-730 (2010).
94. Olesen SS, van Goor H, Bouwense SA, Wilder-Smith OH, Drewes AM. Reliability of static and dynamic quantitative sensory testing in patients with painful chronic pancreatitis. Reg. Anesth. Pain Med. 37, 530-536 (2012).
95. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res. Ther. 13, 211 (2011).
96. Edwards RR, Wasan AD, Bingham CO et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res. Ther. 11, R61 (2009).
97. Roussel NA, Nijs J, Meeus M, Mylius V, Fayt C, Oostendorp R. Central sensitization and altered central pain processing in chronic low back pain: fact or myth? Clin. J. Pain 29, 625-638 (2013).
98. George SZ, Wittmer VT, Fillingim RB, Robinson ME. Fear-avoidance beliefs and temporal summation of evoked thermal pain influence self-report of disability in patients with chronic low back pain. J. Occup. Rehabil. 16, 95-108 (2006).
99. Granot M, Lowenstein L, Yarnitsky D, Tamir A, Zimmer EZ. Postcesarean section pain prediction by preoperative experimental pain assessment. Anesthesiology 98, 1422-1426 (2003).
100. Edwards RR, Mensing G, Cahalan C et al. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. J. Pain Symptom Manage. 46, 30-42 (2013).
101. Yarnitsky D, Crispel Y, Eisenberg E et al. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain 138, 22-28 (2008).
102. Lu J, Xing J, Li J. Prostaglandin E2 (PGE2) inhibits glutamatergic synaptic transmission in dorsolateral periaqueductal gray (dl-PAG). Brain Res. 1162, 38-47 (2007).
103. Belgrade M, Hall S. Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med. 11(12), 1819-1826 (2010).
104. Chappell AS, Desaiah D, Liu-Seifert H et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 11, 33-41 (2011).
105. Burnham LJ, Dickenson AH. The antinociceptive effect of milnacipran in the monosodium iodoacetate model of osteoarthritis pain and its relation to changes in descending inhibition. J. Pharmacol. Exp. Ther. 344, 696-707 (2013).